Preclinical Stuidies
Preclinical studies are a critical step in the development of pet drugs, serving as the cornerstone for transitioning potential drugs from the laboratory to clinical application. Protheragen PawDiscover is a company specializing in drug development for pets such as dogs and cats. We can provide one-stop preclinical study services for clients. Through rigorous scientific methodologies, we conduct comprehensive assessments in validated pet disease models. Our work aims to elucidate key characteristics of drug candidates, including efficacy, in vivo behavior (DMPK/ADME), and safety. These studies deliver essential scientific evidence for subsequent clinical trial design, significantly reducing development risks.
If you are seeking a reliable preclinical studies partner, please feel free to contact us. Let's join forces to safeguard the health of pets worldwide.
Our Services
Protheragen PawDiscover delivers preclinical studies services that strictly adhere to pet drug development regulations, generating high-quality, reproducible scientific data to provide the foundation for subsequent clinical trials.
Efficacy Evaluation
Validates the therapeutic potential of drug candidates against specific pet diseases (e.g., tumors, osteoarthritis, skin disorders, endocrine diseases, infectious diseases) through in vitro and in vivo models.
- In vitro efficacy evaluation
- In vivo efficacy evaluation
DMPK/ADME
Pharmacokinetics and absorption, distribution, metabolism, and excretion (ADME) studies are crucial for understanding how a drug is processed within the pet's body. This is essential for determining dosage regimens and predicting potential drug interactions and toxicity. process development.
- In vitro ADME
- In vivo PK
Target Animal Safety Studies
Evaluates the safety of the drug in healthy target animals (dogs, cats), identifying potential toxicities and determining the safe dosage range. This constitutes a core study for assessing the clinical risks of a new drug.
Process of Our Services
Our Platforms
Bioanalytical Platform
High-sensitivity LC-MS/MS, HPLC-UV, etc.
Cellular and Molecular Biology Platform
Cell culture, PCR/qPCR, Western Blot, ELISA, imaging equipment, flow cytometers, etc.
Pathology Platform
Tissue processing, sectioning, staining, and digital scanning systems, etc.
Why Choose Us?
Expert Team
Our core team comprises seasoned pathologists, pharmacologists, and toxicologists with an average of over 5 years of industry experience. We leverage deep expertise in pet drugs to address complex challenges in pet drug development, effectively mitigating your R&D risks.
Advanced Technology Platforms
We have a range of advanced platforms, such as high-content imaging, LC-MS/MS bioanalysis, and digital pathology. This infrastructure enables precise, efficient evaluation of drug safety profiles, therapeutic efficacy, and pharmacokinetic properties in pets.
High-Quality Data
All studies are strictly conducted in accordance with Good Laboratory Practice (GLP), guaranteeing the accuracy, integrity, and reproducibility of the data. This provides support for the regulatory submission of pet drugs.
Flexible and Efficient Customized Services
We understand that each project is unique. Rejecting a one-size-fits-all approach, we provide flexible and tailored services based on your drug's characteristics, target indications, development stage, and specific budget.
